The launch meeting of Ameile® (Ametinib Mesylate Tablets), a Class 1 innovative drug independently developed by Hansoh Pharma, was successfully held recently. As the world's second and China's first original third-generation EGFR-TKI, the approval and launch of Ameile® filled the gap of third-generation EGFR-TKI in China and aroused strong attention from the society and the media. Recently, important columns or pages of authoritative media such as CCTV-2, CCTV-4, China News Agency, Xinhua News Agency and Economic Daily have all provided feature reports on Ameile®.
With the approach of the launch meeting of Ameile®, two major TV columns, "Finance on the Hour" of CCTV Financial Channel (CCTV-2) and "China News" of Chinese International Channel (CCTV-4), both reported that Ametinib, the first domestic third-generation targeted new drug for lung cancer, was approved by the National Medical Products Administration and would be launched in the near future, bringing a new treatment option to patients with advanced lung cancer.
Caption: Report by Finance on the Hour of CCTV2
Report by China News of CCTV4
The launch meeting of Ameile® received extensive coverage from China News Network, Economic Daily, The Paper and other mainstream media. According to the media, the advent of Ameile® has filled the drug use gap in the domestic lung cancer subdivision, and with the launch of this drug, 150,000-200,000 patients with advanced lung cancer in China will benefit.
Caption: Report by China News Network
Report by Economic Daily
Report by The Paper
Shanghai Daily, the first mainstream English-language newspaper in China, also prominently featured Ameile®, pushing the message to a wider and more diverse audience.
Caption: Report by Shanghai Daily
It is worth mentioning that during the launch meeting of Ameile®, more than 10 platforms, including People's Daily Health Client, Health Times WeChat Live, iQiyi and Tencent Video, aired the whole process live, and more than 10 million viewers watched the meeting online, witnessing the launch of the first domestic third-generation EGFR-TKI innovative drug.
Such extensive coverage reflects the high recognition of Hansoh Pharma and Ameile® from the authoritative and mainstream media. With sheer dedication to innovation, Hansoh Pharma commits itself to making high-quality innovative drugs for clinical use and benefiting the people by creating excellence in pharmaceuticals and enhancing innovation in China.